Genome & Company

Genome & Company


Genome & Company
B-8F Silicon Park, 35 Pangyo-ro 255beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea, 13486


Consent to collection and use of personal information (Required)

Genome & Company (the ”Company”) regards the protection of personal information of our users very important, and complies with relevant laws, including the Personal Information Protection Act and the Act on Expansion of Dissemination and Promotion of Utilization of Information System. The Company hereby informs the purpose and method of using the personal information provided by our users through the Company’s website, and what measures are taken to protect the personal information. If the Company revises any of this Private Policy, it will be notified through the notices on the Company’s website (or individually notified).

1. Items of Personal Information Collected and the Collection Method

The Company collects the following personal information to operate its Contact Service via the Company’s website (whereby the users can make general inquires, inquiry for business development, IR inquiry, media inquiry, etc.).
- Essential Information: name, e-mail address, phone number, organization, content of inquiry
- Collection method: The Company collects the personal information through the inquiries submitted via the Contact Bulletin Board on the Company’s website.

  You have the right to refuse the ‘collection of essential information’ as well as the ‘collection of optional information’. If you refuse the collection of essential information, however, you may be restricted for using the Contact Service.

The following information may be automatically generated and collected in the process of using the website.
- IP Address, cookie, date and time of visit, records of service use

2. Purpose of Collecting Personal Information

The Company uses the collected personal information for the following purposes.
- Personal verification, personal identification, delivery of inquiries and notification of results (answers and responses), etc. related to the use of Contact Service

3. Processing of Personal Information and Retention Period

In principle, the collected personal information is destroyed without any delay after achieving the purpose of collecting and using personal information. However, the Company may keep users’ information for a certain period of time as required by relevant laws.
- Retained information: personal information submitted with the inquiry, content of the inquiry, and ensuing responses
- Relevant Law: Act on the Consumer Protection in Electronic Commerce, etc.
- Retention Period: three years (records related to resolution of consumer complaints or disputes)

4. Destruction of Personal Informatio

In principle, the information is destroyed without any delay after achieving the purpose of collecting and using personal information. The procedure and method of destruction are as follows.

1) Procedure
The personal information submitted is transferred to a separate database (in case of paper, separate cabinet) after achieving the purpose and kept for a certain period of time according to the internal policy and other relevant laws, before it is destroyed. The personal information transferred to separate database shall not be used any other purposes other than for keeping in accordance with laws.

  2) Destruction Method
Personal information saved in the form of electronic file shall be deleted by using technical method that cannot reproduce the records. Personal information printed in the paper shall be destroyed by shredding with a shredder or incinerating it.

5. Consignment of Personal Information Processing

The Company does not consign personal information to a third party. If consignment occurs in the future, it shall be notified through website and the contents of this Privacy Policy shall be updated.

6. Rights of Users and Their Legal Representatives

Users and their legal representative (for the users below the age of 14) may make an inquiry related to or request deletion or modification of their own personal information. In this case, please contact the Company’s Data Protection Manager (see Section 7 of this Privacy Policy) in writing, by phone, or by e-mail so that we can take measures without any delay after verifying your identification.

In case users request the correction of any errors in personal information, we shall not use or provide the personal information until such correction is made. In addition, in case incorrect personal information is already provided to a third party, we will notify the third party the result of correction without delay.

The Company processes and destroys personal information at the request of users or their legal representatives in accordance with Section ‘3. Processing of Personal Information and Retention Period’ and Section ‘4. Destruction of Personal Information’, and such information shall not be opened or used for any other purposes.

7. Information on Data Protection Officer and Manager

The Company designates data protection officer and manager for managing personal information as follows to protect users’ personal information related to inquiries.

Data Protection Officer
Name: Seo Yeong-jin
Department: Business management
Position: Vice-president
Telephone: 031-620-0150

  Data Protection Manager
Name: Seol Su-gi
Department: PR team
Position: Team Lead
Telephone: 070-4821-3840

You can submit to the personnel above any inquiries related to your personal information submitted to the Company while using our web service. The Company will quickly provide sufficient responses to your inquiries.

Please contact the below agencies if you need report or counseling for any infringement of personal data privacy.

- Personal Information Infringement Report Center ( / 118 without area code)
- Personal Information Dispute Mediation Committee ( / 1833-6972)
- Cyber Investigation Department, Supreme Prosecutor’s Office ( / 1301 without area code)
- Cyber Bureau of the National Police Agency ( / 182 without area code)

8. Notification

We will notify users any additions, deletions, and modification on the current Privacy Policy in advance through ‘Notice’ on the Company’s website.

9. Other Websites

We inform you that any collection of personal information by other websites which may be hyperlinked on the Company’s website is not the subject of this Privacy Policy.

Press Release

[Press Release] Scioto Biosciences, a Genome & Company affiliate, publ…

Scioto Biosciences, a Genome & Company affiliate, publish the protective results of ABTplatform in NEC

in medical journal ‘Brain, Behavior and Immunity’


n  Researchers from the Abigail Wexner Research Institute at Nationwide Children’s Hospital in the US, Developers of Activated Bacterial Therapeutics platform technology publish results from a study that looked at the effectiveness of microbiome.

n  “In the future, along with securing a new treatment for NEC, we will continue our efforts to increase efficacy by integrating Scioto Biosciences' ABT platform with other microbiome pipelines”


[12 May 2021] Global microbiome leading company Genome & Company (314130, CEO: Jisoo Pae ∙ Hansoo Park) has announced the effectiveness of a microbiome delivery platform (Activated Bacterial Therapeutic platform, hereinafter referred to as ABT platform) by its affiliate, Scioto Biosciences in an animal model of Necrotizing Enterocolitis (hereinafter referred to as NEC). The results of the animal model study were published in a paper in the medical journal, ‘Brain, Behavior and Immunity’ (Impact Factor, IF: 6.633), by researchers from the Abigail Wexner Research Institute (AWRI) at Nationwide Children's Hospital in the United States.


Through the results of this paper, researchers at AWRI, the original developer of the technology licensed to Scioto Biosciences, showed the efficacy of a single strain of Lactobacillus Reuteri (hereinafter, referred to as L. Reuteri) in the NEC animal model study. In addition, it was revealed that biofilm, formed through the ABT platform, enhance efficacy of microbiome drug, find out possibility of microbiome drug candidates could be developed. As a result of the animal model study, better efficacy was observed when the strain was grafted to the ABT platform technology than the existing L. Reuteri strain alone in reducing the incidence of NEC, preventing cognitive dysfunction and reducing anxiety behavior.


Scioto Biosciences, an affiliate of Genome & Company, has built its proprietary ABT platform that enhances the persistence of strains and holds exclusive licenses worldwide for the platform. The ABT platform is a technology that increases the viability and persistence of the strain by injecting pre-biotics into a specific strain into a microsphere similar to the gastric mucosa environment. Through this technology, Scioto has continued its research and development results confirming the possibility of microbiome as a medicine in areas such as brain diseases, gastrointestinal diseases, and neo-natal diseases.



Dr. Gail Besner, one of the Scientific Founders of Scioto Biosciences led this study, and said, "It was meaningful to confirm the efficacy of a single strain of L. Reuteri and to obtain positive results for the ABT platform technology, in protecting not only the intestines, but also the brain after intestinal injury." “These important results support the neonatal disease of NEC as a future target for microbiome treatment based on the ABT platform,” she added.


Dr. Gail Besner is co-founder of Scioto Biosciences and holds equity in Scioto Biosciences. She has received financial compensation from Scioto for the technology licensed to Scioto Biosciences from Nationwide Children’s Hospital. Dr. Besner may receive additional compensation related to the successful commercialization of the technology


In the case of 'SB-121', microbiome-based therapeutic targeting disorders related to the gut-brain axis, which is one of Scioto biosciences’s major pipelines, it is scheduled to start clinical trials in the first half of 2021 for patients with Autism Spectrum Disorder (ASD). ‘SB-121' is a microbiome medicine candidate researched and developed using the ABT platform. Based on the results of this study, Scioto Biosciences is planning an additional clinical trial for NEC in the first half of next year.


Han-soo Park, CEO of Genome & Company, said, “This publication is a meaningful result that shows the possibility of treating NEC in the absence of existing treatments. In the future, along with securing a new treatment for NEC, we will continue our efforts to increase efficacy by integrating Scioto Biosciences’s ABT platform with other microbiome pipelines.”


On the other hand, Necrotizing Enterocolitis (NEC) is a rare disease that occurs in about 10% of pre-mature infants and about 30% of them die and about 45% of the survivors experience cognitive and neurodevelopmental disorders. The cause of the onset has not been clearly identified, but microbial dysbiosis and pre-mature gut are believed to be the most likely causes.


# # #

[Photo 1] Genome & Company, Scioto Biosciences CI


PREV [Press Release] Scioto Biosciences, Inc announces first patient dosed in Phase Ib study in patients diagnosed with Autistic Disorder
NEXT [Press Release] Genome and Company signs second clinical trial collaboration and supply agreement